Provided by Tiger Trade Technology Pte. Ltd.

Palisade Bio Inc.

1.99
-0.0100-0.50%
Post-market: 2.020.0300+1.51%19:57 EDT
Volume:2.80M
Turnover:5.51M
Market Cap:330.11M
PE:-6.60
High:2.01
Open:2.01
Low:1.90
Close:2.00
52wk High:2.86
52wk Low:0.5300
Shares:165.88M
Float Shares:122.00M
Volume Ratio:0.88
T/O Rate:2.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3014
EPS(LYR):-0.3014
ROE:-24.52%
ROA:-15.54%
PB:2.55
PE(LYR):-6.60

Loading ...

Palisade Bio announces annual shareholder meeting

Reuters
·
Apr 18

Palisade Bio says PALI-2108 Phase 1 ulcerative colitis data set for DDW poster

Reuters
·
Apr 16

Piper Sandler Reaffirms Their Buy Rating on Palisade Bio (PALI)

TIPRANKS
·
Apr 13

Palisade Bio Initiated at Outperform by Wolfe Research

Dow Jones
·
Apr 10

Palisade Bio to present at Needham & Co. annual healthcare conference

Reuters
·
Apr 08

Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB)

TIPRANKS
·
Apr 04

Palisade Bio partners with Iterative Health to advance PALI-2108

TIPRANKS
·
Apr 02

Palisade Bio sells 1.54 million shares in $3 million private placement to Iterative affiliate

Reuters
·
Apr 02

Analysts Have Conflicting Sentiments on These Healthcare Companies: Palisade Bio (PALI) and Moderna (MRNA)

TIPRANKS
·
Apr 01

Palisade Bio reaction to PALI-2108 data ‘looks misaligned’, says Clear Street

TIPRANKS
·
Apr 01

Palisade Bio announces topline data from PALI-2108 trial

TIPRANKS
·
Mar 31

Palisade Bio reports positive Phase 1b PALI-2108 data in fibrostenotic Crohn’s disease

Reuters
·
Mar 31

Palisade Bio Inc - Pali-2108 Shows Favorable Safety With No Serious Adverse Events After Two Weeks

THOMSON REUTERS
·
Mar 31

Palisade Bio Inc - Phase 1B Data Show 47.5% Ses-Cd Reduction; 40% Endoscopic Response and Remission

THOMSON REUTERS
·
Mar 31

Palisade Bio Inc - to Advance Pali-2108 Into Phase 2 Trial in Moderate to Severe Crohn's Disease

THOMSON REUTERS
·
Mar 31

Palisade Bio Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 26

Palisade Bio initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Mar 26

Palisade Bio, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $7

THOMSON REUTERS
·
Mar 26

Palisade Bio Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
Mar 21

Palisade Bio FY 2025 net loss widens 16% to USD 16.78 million, other income jumps 197% to USD 1.29 million

Reuters
·
Mar 21